658.79
+4.75(+0.73%)
Currency In USD
| Previous Close | 654.04 |
| Open | 649.45 |
| Day High | 660 |
| Day Low | 645 |
| 52-Week High | 862 |
| 52-Week Low | 476.49 |
| Volume | 113,512 |
| Average Volume | 1.07M |
| Market Cap | 68.04B |
| PE | 15.79 |
| EPS | 41.72 |
| Moving Average 50 Days | 580.91 |
| Moving Average 200 Days | 596.52 |
| Change | 4.75 |
If you invested $1000 in Regeneron Pharmaceuticals, Inc. (REGN) since IPO date, it would be worth $1,137.81 as of October 31, 2025 at a share price of $658.79. Whereas If you bought $1000 worth of Regeneron Pharmaceuticals, Inc. (REGN) shares 4 years ago, it would be worth $1,200.9 as of October 31, 2025 at a share price of $658.79.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
GlobeNewswire Inc.
Oct 12, 2025 2:18 PM GMT
Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer follow-up showed stability or continued improvement in their hearing Among three who completed s
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
GlobeNewswire Inc.
Sep 30, 2025 8:05 PM GMT
TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2025 financial and operating results on Tuesday, October 28, 2025, before the U.S. financial ma
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
GlobeNewswire Inc.
Sep 26, 2025 11:00 AM GMT
FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) Initial Evkeeza